NOHO LABS
LIVE

Serial Number

99270242

Owner

Eterna Technologies Corporation

Attorney

Thomas Dietrich

Filing Date

Jul 7, 2025

Add to watchlist:

No watchlists yet
View on USPTO

NOHO LABS Trademark

Serial Number: 99270242

NOHO LABS is a trademark filed by Eterna Technologies Corporation on July 7, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Eterna Technologies Corporation (2 trademarks)

Pier 5, Ste. 101
San Francisco, CA 94111

Entity Type: 03

Trademark Details

Filing Date

July 7, 2025

Registration Date

Not Registered

Published for Opposition

March 10, 2026

Goods & Services

Telemedicine services; Health care services for treating aging and loss of biological function through peptide therapy; Providing personalized healthcare and medical information in the nature of peptide therapy; Health care services, namely, peptide therapy; Health care consulting in the field of peptide therapy; Providing healthy lifestyle and nutrition services, namely, personal assessments, personalized routines, maintenance schedules, and counseling

Pharmaceutical preparations for peptide therapy for the treatment and management of musculoskeletal and recovery conditions, namely muscle wasting, sarcopenia, soft tissue injuries, tendon injuries, and wound healing, dermatological conditions, namely skin aging, wrinkles, skin laxity, and hair loss, fatigue, energy, and cognitive conditions, namely chronic fatigue, low energy, age-related cognitive decline, and sleep disorders, age-related conditions, namely growth hormone deficiency, age-related muscle loss, and osteoporosis, inflammatory conditions, namely chronic inflammation and joint inflammation, sexual health disorders, namely erectile dysfunction, hypoactive sexual desire disorder, and hypogonadism, and metabolic disorders, namely obesity, overweight conditions, insulin resistance, and metabolic syndromes; Syringes sold filled with peptide preparations for the treatment and management of musculoskeletal and recovery conditions, namely muscle wasting, sarcopenia, soft tissue injuries, tendon injuries, and wound healing, dermatological conditions, namely skin aging, wrinkles, skin laxity, and hair loss, fatigue, energy, and cognitive conditions, namely chronic fatigue, low energy, age-related cognitive decline, and sleep disorders, age-related conditions, namely growth hormone deficiency, age-related muscle loss, and osteoporosis, inflammatory conditions, namely chronic inflammation and joint inflammation, sexual health disorders, namely erectile dysfunction, hypoactive sexual desire disorder, and hypogonadism, and metabolic disorders, namely obesity, overweight conditions, insulin resistance, and metabolic syndromes; Pharmaceutical preparations for skin care; Therapeutic pharmaceutical for the treatment of aging, hormone imbalance, and other health conditions via peptide therapy; Pharmaceutical preparations for the treatment of aging-related conditions, hormone imbalances, and other health conditions via peptide therapy; Pharmaceutical preparations for the treatment and prevention of aging-related conditions; Diagnostic preparations for medical or veterinary purposes in the nature of peptide substrates; Synthetic peptides for the treatment and management of musculoskeletal and recovery conditions, namely muscle wasting, sarcopenia, soft tissue injuries, tendon injuries, and wound healing, dermatological conditions, namely skin aging, wrinkles, skin laxity, and hair loss, fatigue, energy, and cognitive conditions, namely chronic fatigue, low energy, age-related cognitive decline, and sleep disorders, age-related conditions, namely growth hormone deficiency, age-related muscle loss, and osteoporosis, inflammatory conditions, namely chronic inflammation and joint inflammation, sexual health disorders, namely erectile dysfunction, hypoactive sexual desire disorder, and hypogonadism, and metabolic disorders, namely obesity, overweight conditions, insulin resistance, and metabolic syndromes

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 5, 2026 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 10, 2026 NPUB
PUBLISHED FOR OPPOSITION
Mar 10, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 4, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 10, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 22, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 22, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 22, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 7, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jan 7, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jan 7, 2026 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 12, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 12, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 12, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 25, 2025 GNRN
NON-FINAL ACTION E-MAILED
Nov 25, 2025 GNRT
NON-FINAL ACTION WRITTEN
Nov 25, 2025 CNRT
ASSIGNED TO EXAMINER
Nov 24, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 16, 2025 NWOS
APPLICATION FILING RECEIPT MAILED
Jul 7, 2025 MAFR
NEW APPLICATION ENTERED
Jul 7, 2025 NWAP